iShares China Large-Cap ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares China Large-Cap ETF trades at $35.38, while Vertex Pharmaceuticals Incorporated trades at $529.62 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals.
| FXI | VRTX | |
|---|---|---|
52-Week High | $41.75 | $529.65 |
52-Week Low | $31.59 | $376.62 |
Market Cap | — | $134.25B |
Sector | — | Health |
Enterprise Value | — | $128.37B |
Signals from Pluang's Aura AI — not financial advice
FXI, the iShares China Large-Cap ETF, trades at $36.17, up 0.61% on the day, with a bullish technical signal driven by moving averages. The ETF benefits from China's strong export data and state-backed economic support, though key financial ratios are not disclosed in the provided data. Recent news highlights China's AI and manufacturing strength as positive catalysts.
Outlook is cautiously optimistic given bullish technicals and macroeconomic tailwinds, but risks include U.S.-China tensions and reliance on financials-heavy exposure. The dividend announcement for 2026 provides income appeal, yet investors face volatility from geopolitical and regulatory uncertainties.
No Aura AI signal available yet.
Trailing returns across standard periods
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →